The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

BACKGROUND: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted for all...

Descripción completa

Detalles Bibliográficos
Autores principales: Dintsios, C. M., Beinhauer, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071579/
https://www.ncbi.nlm.nih.gov/pubmed/32172494
http://dx.doi.org/10.1186/s13561-020-00263-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071579/
https://www.ncbi.nlm.nih.gov/pubmed/32172494
http://dx.doi.org/10.1186/s13561-020-00263-2

Ejemplares similares